Sucampo Acquires Vtesse Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Sucampo Pharmaceuticals (SCMP) PT Raised to $21 at Maxim Group; Vtesse 'Could Be a Great Deal'
April 3, 2017 3:20 PM EDTMaxim Group raised its price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $21.00 (from $19.00) while maintaining a Buy rating after the company acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $200 million.
Analyst Jason... More
